Kidney drug tolvaptan put to the test in Real-World japanese patients
NCT ID NCT02847624
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed 1802 Japanese patients with autosomal dominant polycystic kidney disease (ADPKD) who were taking tolvaptan in real-world clinics. Researchers tracked safety and how well the drug slowed kidney growth. The goal was to see if tolvaptan works as well outside controlled trials as it does in them.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tolvaptan
- What this could lead to
- If successful, this study could confirm that tolvaptan safely slows kidney growth in ADPKD patients in everyday clinical practice.
- What could go wrong
- This is an observational follow-up study, not a new treatment test. Results may not apply outside Japan, and tolvaptan can cause liver side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Otsuka Pharmaceutical Co., Ltd.
Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.